Cipla to market Eli Lilly’s insulin products in India

US pharma major Eli Lilly on Monday announced its partnership with Mumbaibased Cipla to market its insulin products — Humalog (Insulin Lispro) and Trulicity (Dulaglutide) — in India. As part of the deal, Lilly will transfer its rights in India to sell, promote, and distribute the two Lilly Diabetes products to Cipla, subject to all regulatory approvals. Cipla stock closed almost 3 per cent at ~958 apiece on the BSE on Monday.